Effects of transdermal mirtazapine on hyporexic rhesus and cynomolgus macaques (Macaca mulatta and Macaca fascicularis).
Macaque
anti-emetic
antidepressant
appetite stimulation
hyporexia
inappetence
mirtazapine
Journal
Journal of medical primatology
ISSN: 1600-0684
Titre abrégé: J Med Primatol
Pays: Denmark
ID NLM: 0320626
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
revised:
28
12
2020
received:
23
11
2020
accepted:
12
01
2021
pubmed:
3
2
2021
medline:
6
10
2021
entrez:
2
2
2021
Statut:
ppublish
Résumé
Hyporexia and weight loss are important indicators of physical and psychological well-being in macaque colonies. An FDA-approved transdermal formulated Mirtazapine (MTZ) shows effectiveness in managing feline hyporexia. This study sought to determine its effectiveness as an appetite stimulant in macaques. Fourteen macaques with idiopathic hyporexia, intractable to conventional management were treated with transdermal MTZ (0.5 mg/kg) topically administered to aural pinnae once daily for 14 days. Qualitative food consumption was monitored daily for 6 months. Body weights were collected prior to treatment, every 2 weeks for the first 6 weeks, 10 weeks, and 6 months post-treatment. Transdermal MTZ significantly reduced the frequency of hyporexia during treatment and monthly for 6 months. No significant increase in weight noted until approximately 6 months post-treatment. Results from this study indicate that a short course of transdermal MTZ is an effective way to increase food consumption in macaques chronically.
Sections du résumé
BACKGROUND
Hyporexia and weight loss are important indicators of physical and psychological well-being in macaque colonies. An FDA-approved transdermal formulated Mirtazapine (MTZ) shows effectiveness in managing feline hyporexia. This study sought to determine its effectiveness as an appetite stimulant in macaques.
METHODS
Fourteen macaques with idiopathic hyporexia, intractable to conventional management were treated with transdermal MTZ (0.5 mg/kg) topically administered to aural pinnae once daily for 14 days. Qualitative food consumption was monitored daily for 6 months. Body weights were collected prior to treatment, every 2 weeks for the first 6 weeks, 10 weeks, and 6 months post-treatment.
RESULTS
Transdermal MTZ significantly reduced the frequency of hyporexia during treatment and monthly for 6 months. No significant increase in weight noted until approximately 6 months post-treatment.
CONCLUSIONS
Results from this study indicate that a short course of transdermal MTZ is an effective way to increase food consumption in macaques chronically.
Substances chimiques
Appetite Stimulants
0
Mirtazapine
A051Q2099Q
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
128-133Informations de copyright
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Johannes CM, Musser ML. Anorexia and the cancer patient. Vet Clin Small Anim. 2019;49:837-854.
Camus SMJ, Blois-Heulin C, Li Q, Hausberger M, Bezard E. Behavioral profiles in captive-bred cynomolgus macaques: towards monkey models of mental disorders? PLoS One. 2013;8(4):e62141.
Crockett CM, Shimoji M, Bowden DM. Behavior, appetite, and urinary cortisol responses by adult female pigtailed macaques to cage size, cage level, room change, and ketamine sedation. Am J Primatol. 2000;52:63-80.
Ulrich-Lai YM, Christiansen AM, Ostrandera MM, et al. Pleasurable behaviors reduce stress via brain reward pathways. Proc Nat Acad Sci. 2010;107:20539-20534.
Johnston JR, Meeker TL, Ramsey JK, Crane MM, Cohen JK, Ethun KF. Utility of automated feeding data to detect social instability in a captive breeding colon of rhesus macaques (Macaca mulatta): a case study on intrafamily aggression. J Assoc Lab Anim Sci. 2020;59:46-57.
Bohn RP, Gilbert MH. Chapter 15 - emergency medicine and critical care for nonhuman primates. In: Abee CR, Mansfield K, Tardiff S, Morris T, eds. Nonhuman Primates in Biomedical Research. Vol. 1. 2nd ed. Amsterdam: Elsevier Academic Press; 2012:359-389.
DeWald LE, Johnson JC, Gerhardt DM, et al. In vivo activity of Amodiaquine against ebola virus infection. Nat Sci Rep. 2019;9:1-12.
Liu DX, Gill A, Holman PJ, et al. Persistent babesiosis in a Rhesus macaque (Macaca mulatta) infected with a simian-human immunodeficiency virus. J Med Primatol. 2014;43:206-208.
Choi YK, Simon MA, Kim DY, et al. Fatal measles virus infection in Japanese Macaques (Macaca fuscata). Vet Pathol. 1999;36:594-600.
Kelly KR, Pypendop BH, Christe KL. Pharmacokinetics of hydromorphone after intravenous and intramuscular administration in male rhesus macaques (Macaca mulatta). J Am Assoc Lab Anim Sci. 2014;53:512-516.
Lee JI, Kim SJ, Park CG Shigella flexneri infection in a newly acquired rhesus macaque (Macaca mulatta). Lab Anim Res. 2011;27:343-346.
Lang CD, Daviau JS, Merton DA, Caraker SM. Adenocarcinoma of the ileocolic junction and multifocal hepatic sarcomas in an aged rhesus macaque (Macaca mulatta). Comp Med. 2013;63:361-366.
Magginis G, Wilk J, Carroll R, Slayden OD. Assessment of progestin-only therapy for endometriosis in macaque. J Med Primatol. 2008;37:52-55.
Christe KL, Valverde CR. The use of a percutaneous endoscopic gastrotomy (PEG) tube to reverse fatal fasting syndrome in a Cynomolgus Macaque (Macaca fascicularis). J Am Assoc Lab Animal Sci. 1999;38:12-15.
Sanderson SL. Nutrition in disease management in small animals. In: Aiello SE, Moses MA eds. Merck Veterinary Manual. 11th ed. Whitehouse Station, NJ: Wiley; 2016:1914-1934.
Clingerman KJ, Summers L. Validation of a body condition scoring systems in Rhesus Macaques (Macaca mulatta): Inter- and intrarater variability. J Am Assoc Lab Animal Sci. 2012;51:31-36.
Brady AG and Carville AAL. Chapter 12 - digestive system diseases of nonhuman primates. In: Abee CR, Mansfield K, Tardif S, Morris T eds. Nonhuman primates in biomedical research. Vol. 2. 2nd ed. Amsterdam: Academic Press; 2012:589-627.
Watanabe N, Omori IM, Nakagawa A, et al. Mirtazapine versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2011;12:CD006528.
Magden ER, Mansfield KG, Simmons JH, Abee CR. Chapter 17 - nonhuman primates. In: Fox JG, Anderson LC, Otto G, Pritchett-Corning KR, Whary MT eds. Laboratory Animal Medicine. Amsterdam: Elsevier Academic Press; 2015:771-930.
Plumb DC. Plumb's Veterinary Drug Handbook. 8th ed. Stockholm: Blackwell Publications; 2015:996.
Quimby JM, Lunn KF. Mirtazapine as an appetite stimulant and anti-emetic in cats with chronic kidney disease: a masked placebo-controlled crossover clinical trial. Vet J. 2013;197:651-655.
Benson KK, Zajic LB, Morgan PK, et al. Drug exposure and clinical effect of transdermal mirtazapine in healthy young cats: a pilot study. J Feline Med Surg. 2017;19:998-1006.
Buhles W, Quimby JM, Labelle D, Williams VS. Single and multiple dose pharmacokinetics of a novel mirtazapine transdermal ointment in cats. Vet Pharmacol Ther. 2017;41:644-651.
Dickman A. Mirtazapine. Drugs in palliative care. New York: Oxford University Press; 2010:333-335.
Berken GH, Weinstein DO, Stern WC. Weight gain, a side effect of tricyclic antidepressants. J Affect Disorders. 1984;7:133-138.
Fernstrom MH. Drugs that cause weight gain. Obes Res. 1995;3:435S-439S.
Hinze-Selch D, Schuld A, Kraus T, et al. Effects of antidepressants on weight and on the plasma levels of leptin, TNF-α and soluble TNF receptors: a longitudinal study in patients treated with amitriptyline or paroxetine. Am Col Neuropsychopharmacol. 1999;23:13-19.
Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatr. 2010;71(10):1259-1272.
Laimer M, Kramer-Reinstadler K, Rauchensauner M, et al. Effect of mirtazapine treatment on body composition and metabolism. J Clin Psychiatry. 2006;67:421-424.
Lee MS, Kang RH, Ji MY, Lee HY, Chang HS, Hahn SW. Association between leptin gene -2548 A/G polymorphisms and mirtazapine-induced weight gain. Abstracts presented at the World Congress of Neuropsychopharmacology 26th CINP Annual Meeting, Munich, Germany, 13-17 July 2008.
Dalla C, Pitychoutis PM, Kokras N, Papadopoulou-Daifoti Z. Sex differences in animal models of depression and antidepressant response. Basic Clin Pharmacol Toxicol. 2009;106:226-233.
LeGates TA, Kvarta MD, Thompson SM. Sex differences in antidepressant efficacy. Neuropsychopharmacology. 2019;44:140-154.
Sramek JJ, Murphy MF, Cutler NR. Sex differences in the psychopharmacological treatment of depression. Dialog Clin Neurosci. 2016;18(4):447-457.
Arguelles J, Enriquez J, Bowen J, Fatjo J. Mirtazapine as a potential drug to treat social fears in dogs: Five case examples. In: Denenberg S. (Ed.), Abstracts presented at the 11th International Veterinary Behaviour 11th Annual Meeting, Samorin, Slovakia, 14-16 September 2017. 10.1079/9781786394583.0000
Giorgi M, Owen H. Mirtazapine in veterinary medicine a pharmacological rationale for its application in chronic pain. Am J Anim Vet Sci. 2012;7:42-47.
Novak MA, El-Mallah SN, Menard MT. Use of the cross-translational model to study self-injurous behavior in human and nonhuman primates. Int Lab Anim Res. 2014;55:274-283.
Alam A, Voronovich Z, Carley JA. A review of therapeutic uses of mirtazapine in psychiatric and medical conditions. Prim Care Companion CNS Disord. 2013;15(5):PCC.13r01525.
Gholyaf M, Sheikh V, Yasrebifar F, Mohammadi Y, Mirjalili M, Mehrpooya M. Effect of mirtazapine on pruritus in patients on hemodialysis: a cross-over pilot study. Int Urol Nephrol. 2020;52:1155-1165.